目的 探讨宫炎平胶囊联合氟罗沙星治疗慢性盆腔炎的临床疗效。方法 选取2014年7月—2017年7月在郑州市第十五人民医院进行治疗的慢性盆腔炎患者180例，根据入院号分为对照组（90例）和治疗组（90例）。对照组口服氟罗沙星片，0.4 g/次，1次/d；治疗组在对照组的基础上口服宫炎平胶囊，0.75 g/次，3次/d。两组患者均经过4周治疗。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善时间、血清学指标及盆腔炎性包块直径和盆腔积液量。结果 治疗后，对照组和治疗组临床总有效率分别为83.33%和96.67%，两组比较差异具有统计学意义（P < 0.05）。治疗后，治疗组患者临床症状改善时间均显著短于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组血清白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、单核细胞趋化蛋白-1（MCP-1）、血红素氧和酶-1（HO-1）水平均显著降低（P < 0.05）；且治疗组患者这些血清学指标水平明显低于对照组（P < 0.05）。治疗后，两组患者盆腔炎性包块直径明显缩小，盆腔积液量明显减少，同组比较差异具有统计学意义（P < 0.05）；且治疗组上述指标改善后水平明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 宫炎平胶囊联合氟罗沙星治疗慢性盆腔炎可有效降低机体炎症反应，促进临床症状改善，具有一定的临床推广应用价值。

Objective To investigate the clinical curative effect of Gongyanping Capsules combined with fleroxacin in treatment of chronic pelvic inflammatory. Methods Patients (180 cases) with chronic pelvic inflammatory in Zhengzhou Fifteenth People's Hospital from July 2014 to July 2017 were divided into control (90 cases) and treatment (90 cases) groups based on admission number. Patients in the control group were po administered with Fleroxacin Tablets, 0.4 g/time, once daily. Patients in the treatment group were po administered with Gongyanping Capsules on the basis of the control group, 0.75 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the time of clinical symptom improvement, serum cytokine levels, pelvic inflammatory mass diameter, and pelvic effusion volume in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 83.33% and 96.67%, respectively, and there were differences between two groups (P < 0.05). After treatment, the time of clinical symptom improvement in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the IL-1β, TNF-α, MCP-1 and HO-1 levels in two groups were significantly decreased (P < 0.05), and the serum cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the pelvic inflammatory mass diameter in two groups was significantly reduced, pelvic effusion volume was significantly decreased, and the difference was statistically significant in the same group (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Gongyanping Capsules combined with fleroxacin in treatment of chronic pelvic inflammatory can effectively reduce inflammation and improve the clinical symptoms, which has a certain clinical application value.